Editorial: High Baseline ALT Level Confers Risk of Hepatic Adverse Events During Immune Checkpoint Inhibitors Treatment: A Call for Caution-Authors' Reply

Aliment Pharmacol Ther. 2025 Jan 7. doi: 10.1111/apt.18491. Online ahead of print.

Yi-Ping Hung^{1

2

3}, Yi-Hsiang Huang^{2

3

4

5

6}

¹ Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
² Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
³ School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
⁴ Division of Gastroenterology and Hepatology, Taipei Veterans General Hospital, Taipei, Taiwan.
⁵ Healthcare and Services Center, Taipei Veterans General Hospital, Taipei, Taiwan.
⁶ Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.

No abstract available

Publication types